# US 2005/0089999 A1 · Method for the production and purification of adenoviral vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0089999 A1
- Document ID: US20050089999A1
- Status: Published application
- Kind: A1
- Application number: 10/909,066
- Filed: 2004-07-30
- Published: 2005-04-28
- Earliest claimed: 1996-11-20
- Assignees: Introgen Therapeutics, Inc.
- Inventors: Shuyuan Zhang; Capucine Thwin; Zheng Wu; Toohyon Cho; Deborah Wilson; Lucetta Caston
- Web page: https://patentgrep.com/patent/US20050089999A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/761: Adenovirus
- C07K 14/4746: {p53}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/10045: Special targeting system for viral vectors
- C12N 2710/10051: Methods of production or purification of viral material
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10351: Methods of production or purification of viral material
- C12N 2810/6018: Adenoviridae
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

## Claims

### Claim at position 1

1-69. (canceled)

### Claim 70

The method for making a purified adenovirus composition for therapeutic use comprising:
a) growing host cells in a media comprising glucose;
b) infecting said host cells with an adenovirus;
c) lysing said host cells by a lysis method other than freeze-thaw to produce a lysate comprising said adenovirus composition; and
d) purifying adenovirus from said lysate to provide a purified adenovirus composition for therapeutic use.

### Claim 71 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use comprises 70%+/−10% of the starting PFU.

### Claim 72 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use comprises a substantially purified therapeutic adenovirus composition.

### Claim 73 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use has a contaminating nucleic acid concentration of less than 0.8 ng/ml.

### Claim 74 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use has a contaminating nucleic acid concentration of less than 0.2 ng/ml.

### Claim 75 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use has an A260/A280 ratio of between about 1.2 and 1.3.

### Claim 76 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use has an A260/A280 ratio of 1.27+/−0.03.

### Claim 77 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use has a contaminating nucleic acid concentration of less than 0.8 ng/ml and an A260/A280 ratio of between about 1.2 and 1.3.

### Claim 78 (depends on 70)

The method of claim 70, wherein the purified adenovirus composition for therapeutic use has a BSA content below the detection level of a western blot assay.

### Claim 79 (depends on 70)

The method of claim 70, wherein the media is serum-free.

### Claim 80 (depends on 70)

The method of claim 70, wherein the host cells are grown in a bioreactor.

### Claim 81 (depends on 70)

The method of claim 70, wherein the host cells are grown on microcarriers.

### Claim 82 (depends on 70)

The method of claim 70, wherein said purified adenovirus composition for therapeutic use comprises an adenoviral vector encoding an exogenous gene construct.

### Claim 83 (depends on 82)

The method of claim 82, wherein said exogenous gene construct is operatively linked to a promoter.

### Claim 84 (depends on 83)

The method of claim 83, wherein said promoter is SV40 IE, RSV LTR, β-actin, CVM IE, adenovirus major late, polyoma F9-1, or tyrosinase.

### Claim 85 (depends on 82)

The method of claim 82, wherein said exogenous gene construct encodes a therapeutic gene.

### Claim 86 (depends on 85)

The method of claim 85, wherein said therapeutic gene encodes antisense ras, antisense myc, antisense raf, antisense erb, antisense src, antisense fms, antisense jun, antisense trk, antisense ret, antisense gsp, antisense hst, antisense bcl, antisense abl, Rb, CFTR, p16, p21, p27, p57, p73, C-CAM, APC, CTS-1, zac1, scFV ras, DCC, NF-1, NF-2, WT-1, MEN-1, MEN II, BRCA1, VHL, MMAC1, FCC, MCC, BRCA2, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, GM-CSF, G-CSF, thymidine kinase or p53.

### Claim 87 (depends on 86)

The method of claim 86, wherein said therapeutic gene encodes p53.

### Claim 88 (depends on 70)

The method of claim 70, wherein said purified adenovirus composition for therapeutic use is a replication-incompetent adenovirus.

### Claim 89 (depends on 88)

The method of claim 88, wherein said purified adenovirus composition for therapeutic use is lacking at least a portion of the E1-region.

### Claim 90 (depends on 89)

The method of claim 89, wherein the purified adenovirus composition for therapeutic use is lacking at least a portion of the E1A and/or E1B region.

### Claim 91 (depends on 70)

The method of claim 70, wherein said host cells are capable of complementing replication.

### Claim 92 (depends on 70)

The method of claim 70, wherein said host cells are 293 cells.

### Claim 93 (depends on 70)

The method of claim 70, wherein said lysate is treated with a nuclease.

### Claim 94 (depends on 70)

The method of claim 70, wherein said purified adenovirus composition for therapeutic use comprises a pharmaceutically acceptable buffer.

### Claim 95 (depends on 94)

The method of claim 94, wherein said purified adenovirus composition for therapeutic use provides a unit dose of between 103 and 1015 PFU/dose.

### Claim 96 (depends on 94)

The method of claim 94, wherein the purified adenovirus composition for therapeutic use provides a unit dose of between 1010 and 1014 PFU/dose.

### Claim 97 (depends on 70)

The method of claim 70, wherein said purifying is characterized by a process that includes at least one chromatography step capable of providing a purified therapeutic adenovirus composition.

### Claim 98 (depends on 70)

The method of claim 70, wherein said purifying is characterized by a process that includes a single chromatography step capable of providing a purified therapeutic adenovirus composition.

### Claim 99 (depends on 70)

The method of claim 70, wherein the lysis method other than freeze-thaw is a process that includes hypotonic solution, hypertonic solution, impinging jet, microfluidization, detergent, liquid shear, high pressure extrusion, autolysis or sonication to produce a crude lysate composition comprising adenovirus.
